Until 1990, the survival of children with acute lymphoblastic leukaemia (ALL) in Russia was below 10%. To establish a protocol feasible under conditions there, ALL-MB 91 was designed to avoid prolonged bone marrow aplasia, thereby reducing needs for extensive supportive care, blood transfusions, long-lasting hospitalization and costs. High-dose therapies were avoided, anthracycline use was limited and CNS radiation therapy only foreseen in high-risk patients (about 30%). This was randomized against a modified BFM protocol. From 1995 to 2002, 834 patients of age up to 18 years were registered in 10 centres and 713 received after central randomization the allocated risk-stratified treatment. After a median follow-up of 7 years, the event-free survival (EFS) was 67 ± 3% on ALL-MB 91 (N ¼ 358) vs 68 ± 3% on ALL-BFM 90m (N ¼ 355). The overall survival (OS) was 71±3% vs 74±2%, respectively. Anaemia, thrombocytopenia, agranulocytosis 410 days and hospitalization (median 35 vs 68 days) were lower on ALL-MB 91 (Po0.01, N ¼ 197). While EFS and OS were similar with both protocols, ALL-MB 91 significantly incurred fewer toxicity and resource requirements and, therefore, has been increasingly used across Russia.
Introduction
Until the 1980s, the prognosis of children with acute lymphoblastic leukaemia (ALL) was extremely poor in Russia. 1, 2 There was no common standardized treatment protocol. First attempts to use modern intensive therapies gave poor results because of severe, mostly infectious complications and insufficient experience to manage them adequately due to lack of supportive care, mostly due to financial constraints. Patients had to be hospitalized for long periods of time, and because of lacking accommodation facilities and long distances between their homes and the treatment institutions, the patients and their families were living in the hospital wards for months. Infections, in particular hepatitis B, transmitted by contaminated blood products, led to poor tolerance to treatment and thereby considerable delays. The protocol adherence varied largely, resulting in disparate survival rates. 3, 4 Hence, to offer these children a realistic chance for cure, there was an urgent need for a structured cooperative treatment approach, using a feasible protocol adapted to the specific requirements of the Russian conditions with consequent supportive care, accompanied by the advice and supervision of experienced paediatric haemato-oncologists, as well as offers to train Russian physicians and nurses abroad.
After careful considerations, protocol ALL-MB 91 was designed based on data from international trials, including the German ALL-BFM 76/79, 81/83 and 86 trials, [5] [6] [7] [8] the Dutch DCLSG ALL-5 and ALL-6 trials 9,10 and the Dana-Farber consortium trials DFCI 81-01 and 85-01. [11] [12] [13] General aims were to use combination chemotherapy aiming at avoiding deep and long-lasting periods of bone marrow aplasia, thereby reducing the needs for extensive supportive care, the frequency of blood transfusions, long-lasting hospitalization and also costs. The cumulative doses of anthracyclines were limited, high-and intermediate-dose therapies avoided and preventive radiation therapy of the central nervous system (CNS) was only foreseen in high-risk patients (HRG, about 30% of the total population).
During 1991 and 1995, protocol ALL-MB 91 was introduced in a single centre (Republican Children's Hospital, Moscow, Russia) and found to be at least as feasible and similarly effective but accompanied with less side-effects than the 'standard' ALL-BFM 90m protocol. 14, 15 Since then, a network of 10 paediatric oncology and haematology centres in Russia was established and trained in the treatment of ALL in children within the context of these protocols.
From 1995 until 2002, children with newly diagnosed ALL in these centres were randomized to be treated according to either protocol ALL-MB 91 or protocol ALL-BFM 90m in a multicentric comparison. The results of this study are described below.
Patients and methods

Patients
From 1 August 1995 to 30 April 2002, 848 unselected consecutive patients up to 18 years of age with newly diagnosed precursor B-or T-cell ALL were assessed for eligibility in the 10 participating centres in Russia. Fourteen patients were ineligible because they died before accrual procedures (N ¼ 5), their family declined any treatment (N ¼ 6), leukaemia was a secondary malignancy (N ¼ 2) or a storage disease existed (N ¼ 1). Written informed consent for enrolment to this study was obtained from the patient's guardians and the patient, if applicable, but was refused in 73 patients. After randomization of 761 enrolled patients, 713 patients (94%) were treated according to the allocated treatment arm (Table 1A) and are reported on in the following study. The study was carried out in accordance with the World Medical Association's Declaration of Helsinki regarding the ethical principles for medical research involving human subjects. It had been approved before its start by the review board of the competent Russian Federal Clinical Research Centre for Paediatric Haematology, Oncology and Immunology.
Diagnosis
The diagnosis of precursor B-or T-cell ALL required the presence of 425% lymphoblasts (L1 or L2 morphology) in the bone marrow, and it was made by cytomorphological and cytochemical examination of blood and bone marrow smears at the local centre. CNS involvement was defined as 45 nucleated cells per microlitre cerebrospinal fluid, with clearly detectable leukaemic blasts in the absence of major blood contamination (o17 erythrocytes per microlitre) or as leukaemic CNS infiltration. Immunophaenotyping of the leukaemic cells was performed by four reference laboratories according to standardized procedures if bone marrow blast portion exceeded 60%. 16 Due to unavailability under the prevailing health care system, immunophaenotyping could only be performed in 566 (79%) and cytogenetic or molecular genetic tests in 180 (25%) out of the 713 patients. Posteroanterior and lateral chest radiographs were obtained in all patients before treatment initiation, and patients with a mediastinal mass or thymic involvement were regarded as having precursor T-cell leukaemia. 17 
Treatment
After randomization, patients were stratified into the risk groups as defined in the protocols (Table 1B) Standard risk group Á Initial WBC o50 000 ml Block-wise and cumulative dosages as well as timing schedules are presented in Table 2 for patients on ALL-MB 91 and non-HRG patients on ALL-BFM 90m. HRG patients on ALL-BFM 90m were treated with 5-day alternating high-risk blocks (initially as used in protocol ALL-BFM 90 20 and from 1995 on as in protocol ALL-BFM 95, not tabulated).
Supportive care measures had been standardized 15 and were specified in the protocol, such as for prophylaxis and treatment of infections, gastritis and peptic ulcers, for management of adverse reactions to L-asparaginase, for blood component substitution and leukapheresis as well as for initial emergency situations, including tumour lysis syndrome, mediastinal tumour with trachea compression, superior vena cava syndrome, 
Study design and management
The purpose of this study was to compare the new protocol ALL-MB 91 with respect to survival as well as toxicity and cost indicators against the control protocol ALL-BFM 90m. Event-free and overall survival probabilities were primary endpoints. Complete remission rate, frequencies and distributions of toxicity-related data were secondary end points. ALL-MB 91 was not expected to be superior to ALL-BFM 90m with regard to survival, but better manageable and less costly while maintaining acceptable survival rates. To support that the new protocol was not inferior to control, the confidence interval of the difference in their event-free survival (EFS) probabilities was considered according to Machin D and Gardner MJ 21 and Piaggio G et al. 22 in advance of further analyses as specified in the protocol. Risk-group-specific comparisons were not possible because definitions varied largely between the protocols. In a blinded fashion, enrolled patients were centrally randomized by the trial coordination centre (Research Institute for Paediatric Haematology and Oncology, Moscow) using a randomization list with equal probabilities for the two protocols.
The coordination centre continuously monitored the trial, receiving reports on accrual, treatment course and events from participating centres, and requesting status updates and the resolution of pending queries at least every 6 months. Telephone consultation and email were used throughout the study to exchange information.
For toxicity analysis, full on-site patient record analysis was performed for the first 197 of 713 (28%) patients receiving the allocated protocol. Patients in this analysis were included consecutively irrespective of site after completion of intensive treatment phases and representativity was assessed at study completion. 20 and from 1995 on as in protocol ALL-BFM 95, their blockwise and cumulative drug dosages are not shown due to small number of patients (Table 3 ) and variable number of blocks. ALL-MB 91: given on day 22 to all patients in HRG or to patients in SRG with 410% BM blasts on day 15. 
Statistical analysis and definitions
Estimates of EFS, disease-free (DFS) and overall survival (OS) probability ( ± standard error) were calculated by Kaplan and Meier's method 23 and were compared using the log-rank test. 24 Cumulative incidences were estimated according to Kalbfleisch and Prentice, 25 and plots and statistical comparisons were produced using Gray's methods. 26, 27 The accrual of 50 patients per protocol annually for 7 years, zero drop-in or dropout rates and an estimated EFS probability of 0.67 at 10 years would have provided for a power of 0.75 at a type I error of 0.05 to detect a clinically meaningful absolute survival difference of 10% or more. 28 Results are reported for analyses in the per-protocol population (by protocol received as allocated by randomization, N ¼ 713; Table 1A and 1B), if not stated otherwise; for comparison, analyses in the intention-to-treat population (as randomized to protocol, N ¼ 755; Table 1A and 1B) were carried out.
Events were non-response, relapse, second malignancy and death in case of EFS, relapse and death in case of DFS and death in case of OS. Survival times were calculated from attaining complete remission until event for patients who failed or until the date of last status report for patients who did not fail. Patients who did not attain complete remission, that is, those who died early and those with non-response were considered to have zero EFS time. Non-response was defined as more than 5% lymphoblasts in the bone marrow on day 36 (ALL-MB 91) or on day 33 (ALL-BFM 90m) of treatment, whereas the original definition in protocol ALL-BFM 90 would not be applicable until the completion of three further treatment blocks. Patients allocated to either protocol went off-study upon non-response, with an event, and are included in this study only in respect of OS, although some patients were further treated with BFM HRG blocks (see Treatment).
Frequencies and distributions were compared with the w 2 or Fisher's exact test and with the U-test, respectively. For calculations, Graphpad Prism version 3.0 (GraphPad Software Inc., San Diego, CA, USA), Statistica version 6.0 (Statsoft Inc., Tulsa, OK, USA), and R version 2.4.0 were used on a database frozen on 1 March 2006.
Results
Patient characteristics
Characteristics of the 713 patients receiving the protocol allocated by randomization and analysed in this study are detailed in Table 3 . Time from diagnosis to randomization was median 0 days (maximum, 2 days). In patients without event, the median follow-up time was 6.6 (interquartile range (IQR), 3.9-10.6) years on protocol ALL-MB 91 and 6.8 (IQR, 3.9-10.6) years on protocol ALL-BFM 90m. No protocol crossover occurred. Eight patients were lost to follow-up and censored in the analyses at 852, 1398, 1691, 2053, 2233, 2304, 2422 and 2462 days after diagnosis. The distribution of the baseline risk factors, such as sex, age, white blood cell count, CNS involvement and immunophaenotype (Table 3) , were not different between patients on either protocol.
Outcome
The estimates of the EFS probability projected at 10 years were 67±3% (N ¼ 358) on protocol ALL-MB 91 and 68±3% (N ¼ 355) on protocol ALL-BFM 90m (P log-rank ¼ 0.66, Table 3 , Figure 1a ). The 95% two-sided confidence interval of this À1% difference in EFS probability estimates was À9 to þ 7%. At this level of confidence, an inferiority of ALL-MB 91 to ALL-BFM 90m by 10% or more of absolute EFS probability can be excluded.
The estimates of OS probability projected at 10 years were 71 ± 3% and 74 ± 2% (P log-rank ¼ 0.68, Table 3, Figure 1b ) and the estimates of DFS probability were 75±2% and 75±3% (P log-rank ¼ 0.94) in patients on protocol ALL-MB 91 and ALL-BFM 90m, respectively. For comparison, in the intention-to-treat population, the estimates of DFS probability projected at 10 years were 74±2% (ALL-MB 91; N ¼ 339 patients, who had obtained remission) and 75 ± 2% (ALL-BFM 90m; N ¼ 337; P log-rank ¼ 0.63).
The cumulative incidence curves of relapses under competing risks in patients who had obtained remission were not different by protocol (Figure 2 , P Gray X0.3 for all relapse types). On protocol ALL-MB 91, isolated CNS relapses occurred in eight HRG patients (7.1% of HRG, 2.2% of protocol patients, Table  4A and 4B) and in only two standard risk group patients (0.8% of SRG and 0.6% of protocol patients). Among all 10 patients with isolated CNS relapses, 5 had an initial white blood cell count 4100 000 ml À1 .
Toxicity
During the first days of treatment, two and five of the patients on protocols ALL-MB 91 and ALL-BFM 90m, respectively, died from hyperleukocytosis, encephalopathy or bleeding. During further induction treatment, 11 and 17 patients died from sepsis or pneumonia (9/15 patients on protocol ALL-MB 91/ALL-BFM 90m, respectively), necrotizing enterocolitis (1/1), chicken pox (0/1) and adrenal insufficiency (1/0). Causes of death in complete remission were infection (sepsis and pneumonia, 7/2 or necrotizing enterocolitis, 0/2), massive bleeding (2/2), necrotizing pancreatitis (1/1), catheter complications (1/0) or were unknown (1/0). There were no significant differences in the rates of early deaths, deaths in complete remission , relapses and secondary malignancies (one frontal lobe brain tumour) between the protocols (Table 4A) . Toxicity as defined by grades of anaemia, thrombocytopenia and agranulocytosis of more than 10 days duration is summarized in Table 4B in relation with the intensive treatment phases. Notably, during induction therapy, no difference could be found for the above-mentioned parameters, whereas during Consolidation I/Protocol Ib and Consolidation II/Protocol M, the haematological toxicity was significantly lower in patients on ALL-MB 91. In Consolidation III/Protocol II of this protocol, toxicity was significantly lower in patients only with respect to platelet counts. The duration of hospitalization was markedly less for patients on protocol ALL-MB 91 (median 35 days; IQR, 19-61 days) compared to those on protocol ALL-BFM 90m (median 68 days; IQR, 40-99 days; P U test o0.001). Avascular bone necroses occurred in two patients on protocol ALL-BFM 90m and in no patient on ALL-MB 91.
Discussion
The efficacy and toxicity were compared between a slightly modified version of the internationally established protocol ALL-BFM 90 and a new protocol ALL-MB 91 designed for the treatment of children with newly diagnosed precursor B-or T-cell lymphoblastic leukaemia in Russia in a randomized multicentre study.
The study demonstrated that the EFS on protocol ALL-MB 91 was not inferior to that on protocol ALL-BFM 90m, at a 10% Protocol ALL-MB 91 for treatment of childhood ALL in Russia A Karachunskiy et al Response rates at day 8 (peripheral blast count o1000 ml À1 ) and day 15 (blast portion o25% in normocellular bone marrow) were slightly lower to significantly lower, in patients on protocol ALL-MB 91 compared with ALL-BFM 90m. Response at day 8 was associated with favourable EFS and OS (about 72 and 77%), but there were no differences in EFS or OS between both protocols. Response at day 15 was associated with slightly favourable to significantly favourable EFS and OS for patients on protocol ALL-MB 91 compared with ALL-BFM 90m, partly compensating for the slightly higher rate of non-response on protocol ALL-MB 91. During the further course of patients in remission, the time points and types of relapses were not different between the two protocols, as shown in the cumulative incidence curves (Figure 2) .
Characteristic features of the newly designed protocol ALL-MB 91 are: the extended use of asparaginase, of dexamethasone and of prolonged intrathecal therapy instead of cranial radiation therapy for the majority of patients; the omission of intermediate-and high-dose methotrexate and cyclophosphamide and very low or moderate cumulative doses of anthracyclines for standard or high-risk patients, respectively.
The superior antileukaemic efficacy of dexamethasone compared to prednisone was demonstrated in several trials. 9, 10, 12 It can be explained by a higher affinity of the steroid receptor, less protein binding, more readily crossing of blood brain barrier, longer half-lives in serum and cerebrospinal fluid of dexamethasone. 30, 31 Its use in protocol ALL-MB 91 was (Table 1B) is shown for protocols (c) ALL-MB 91 and (d) ALL-BFM 90m. P refers to the log-rank test. Figure 2 Cumulative incidences of different types of relapses in children with acute lymphoblastic leukaemia (ALL) by protocol. The incidence estimates of relapses over time are shown, comparing protocol ALL-MB 91 with ALL-BFM 90m: isolated bone marrow (BM) relapse (P Gray ¼ 0.3), isolated central nervous system relapse (P Gray ¼ 0.3) and other relapse (P Gray ¼ 0.9). In brackets, estimates at 10 years. Risks competing with relapse: death in remission, second malignoma; censored: no event, lost to follow-up, non-response, death during induction. (CCG) 1992 19 trials at a dose of 6 mg m -2 day À1 , which had not been associated with thromboembolic events or avascular bone necrosis. Nevertheless, dexamethasone was not more effective on day 8 as randomly compared to prednisone in this study.
Protocol ALL-MB 91 for treatment of childhood ALL in Russia
The antileukaemic efficacy of weekly administered L-asparaginase was demonstrated in trials by the Dana-Farber Cancer Institute, [11] [12] [13] 32 especially for consolidation. In addition, its intramuscular injection, as in protocol ALL-MB 91, has been shown in a Children's Cancer Study Group (CCSG) trial to be equally effective, but less toxic, than intravenous administration. 33 Central nervous system-directed antileukaemic treatment in protocol ALL-MB 91 relied on extended dexamethasone use, on intensified L-asparaginase to more continuously deplete cerebrospinal fluid of asparagine, and also on prolonged use of triple intrathecal therapy. Compared to cranial radiation therapy, several trials have shown sufficient protection against CNS relapses by prolonged intrathecal therapy, 33, 34 except in children with T-cell phenotype or initial CNS involvement. 20 Central nervous system-directed antileukaemic treatment in protocol ALL-BFM 90m included cranial radiation therapy for standard and intermediate-risk patients to compensate for the reduction from high, as in original ALL-BFM 90, to intermediate dose of methotrexate required, because reliable facilities for prompt methotrexate serum level monitoring were not available. However, the specific contribution of high-dose methotrexate to the CNS-directed antileukaemic effect is not known because it had been introduced at the same time as a different dosing regime for intrathecal methotrexate into, for example, trial ALL-BFM 86. 8 There is intriguing evidence that basing the dosing regime for intrathecal methotrexate on age, rather than on body surface area, readily reduces CNS relapse rates from 8-27% to 2-6%. 35 As a consequence, CNS-directed therapy differed markedly between the protocols. Only about 30% of patients on ALL-MB 91 but more then 67% on ALL-BFM 90m (ImRG and HRG) received cranial radiation therapy. The incidence of isolated CNS relapses on protocol ALL-MB 91 (2.8%) was slightly higher than that on ALL-BFM 90m, but it was only 0.8% in standard risk group patients, comparable with international results. 36 Remarkably, this favourable rate of isolated CNS relapses in SRG patients (about 70% of patients) on ALL-MB 91 was obtained using neither intermediate-or high-dose methotrexate nor cranial radiation therapy.
Applying the National Cancer Institute (NCI)/Rome criteria in precursor B-cell ALL, no statistically significant difference in EFS probability between protocol ALL-MB 91 and ALL-BFM 90m could be detected (Table 3) .
Due to unavailability of facilities and trained personnel in Russia at that time, results from immunophaenotyping and cytoor molecular genetic characterizations were available only in 79 and 25% of the patients, respectively, in this study. However, considering the low Ph þ ALL incidence of less than 3.5% among Caucasian children and adolescents with ALL, 37 and their increased, but not universal failure to achieve complete remission (about 15%), the interpretation of our results would remain valid even if such patients had been over-represented in ALL-BFM 90m.
Although protocol ALL-MB 91 did not introduce new drugs for the treatment of ALL in children, the chemotherapy design was completely newly composed according to the available efficacy data. These new induction, consolidation and maintenance blocks apparently allowed for a different course of leukaemic cell clearance and, possibly even more important, for less treatment-related compromise of haematological and Abbreviations: BFM, Berlin-Frankfurt-Mü nster; CTCAE, common terminology criteria for adverse events; Hb, haemoglobin; MB, Mascow-Berlin; Thr, thrombocytes. By protocol, the numbers of patients experiencing toxicity/numbers of patients exposed are given. The table is based on the first 197 patients (cf. Patients and methods section). Haemoglobin o7 g per 100 ml corresponding to anaemia of CTCAE grade 3 (o8 g per 100 ml) or 4 (o6.5 g per 100 ml). Thrombocyte counts o20 per nl corresponding to thrombocytopenia of approximately CTCAE v3.0 grade 4 (o25 per nl). Long-lasting (more than 10 consecutive days) agranulocytosis (neutrophils o0.5 per nl), corresponding to agranulocytosis of CTCAE v3.0 grade 4.
Protocol ALL-MB 91 for treatment of childhood ALL in Russia A Karachunskiy et al physiological function, as reflected by the response and toxicity data. In this study, toxicity analysis focussed on the acute haematological toxicity, because it determines feasibility and costs of intensive and supportive treatment; late effects are still under registration. Protocol ALL-MB 91 resulted in less toxicity compared to protocol ALL-BFM 90m during intensive treatment after induction. During induction, there was a trend towards a lower portion of patients suffering an early death or experiencing long-lasting agranulocytosis on protocol ALL-MB 91. Since toxicity during induction, however, is significantly resulting from disease-related bone marrow insufficiency, protocol ALL-MB 91 appears favourable with respect to both, hazards during induction and haematological toxicity incurred after induction.
When ALL-BFM 90m was adopted in Russia as a first 'standard guideline', significant treatment delays occurred in one third of patients because of treatment-related toxicity. 4, 38 However, along with this adoption, physician and nursing practices were greatly advanced, and inter-centre cooperation was initiated. EFS of children with ALL increased from 5-10% 39, 40 to about 60%. In the 10 centres participating in this study protocol, ALL-BFM 90m was performed with results approaching internationally obtained results. 40 The randomized multicentric comparison of ALL-MB 91 with ALL-BFM 90m in this study demonstrated that both protocols were feasible and equally successful under conditions of the Russian health-care system. There were virtually no differences concerning the EFS curves over the range of 10 years ( Figure 1 ) and rates of remission, course of relapses (Figure 2) , and fatal complications were also in harmony between both protocols.
Nevertheless, the supposed advantages of the new protocol ALL-MB 91 were confirmed, such as a lower haematological toxicity with diminished morbidity and hospitalization, which have been reported to translate into cost reductions (relative estimated costs of intensive treatment for non-HRG patients of ALL-MB 91 vs ALL-BFM 90m, 1:1.35). 15 It is also reasonable to expect that protocol ALL-MB 91 will ultimately result in lesser frequencies of adverse long-term sequelae due to the reduced exposure of the CNS to radiation therapy and the much lower exposure of the heart to anthracyclines.
In the mean time, the positive experience with ALL-MB 91 has led to a widespread acceptance of the protocol and the formation of a Russian ALL study group. ALL-MB 91 has become the basis for the current trial ALL-MB 2002 with 37 participating institutions across Belarus and Russia, recruiting between 400 and 500 patients per year.
In most highly developed western countries, the treatment of childhood ALL has become more and more sophisticated with stratification based on molecular genetic findings, monitoring of minimal residual disease and rather complex multidrug chemotherapy schedules. The introduction of these techniques has led to a moderate further increase of cure rates but also to constantly increasing costs. The ALL-MB group aims at developing an effective and feasible treatment while keeping the costs affordable, using simple clinical stratification criteria and limiting acute and long-term toxicity. As shown, with this concept, it has been possible to achieve results approaching even to international standard protocols at that time. 36, 40, 41 In our opinion, the ALL-MB 91 concept might be an interesting and attractive option for countries with less developed health systems and limited resources, which still constitute the larger part of the world population. Furthermore, the results support the assumption that less intensive therapy may be sufficient for a population of children with ALL and standard risk features even in countries with well-developed health-care systems.
